inegy 10 mg/40 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin40 mg / 1 tableta; simvastatin 40 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/20 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin20 mg / 1 tableta; simvastatin 20 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/10 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin10 mg / 1 tableta; simvastatin 10 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/80 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin80 mg / 1 tableta; simvastatin 80 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/20 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin20 mg / 1 tableta; simvastatin 20 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/80 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin80 mg / 1 tableta; simvastatin 80 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/40 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin40 mg / 1 tableta; simvastatin 40 mg / 1 tableta - simvastatin in ezetimib
inegy 10 mg/10 mg tablete
merck sharp & dohme, d.o.o. - ezetimib; simvastatin - tableta - ezetimib 10 mg / 1 tableta simvastatin10 mg / 1 tableta; simvastatin 10 mg / 1 tableta - simvastatin in ezetimib
azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine accord
accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine soglasju je indicirano za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:- intermediate-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),- kronično myelomonocytic levkemijo (cmml) z 10-29 % mozga eksplozije brez myeloproliferative motnje,- akutno mieloično levkemijo (aml) z 20-30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who), in razvrščanje,- aml s >30% mozgu eksplozije glede na razvrstitev, ki.